Epstein-Barr virus antibodies and risk of multiple sclerosis: A prospective study

JAMA

Volumn 286, Issue 24, 2001, Pages 3083-3088

  Ascherio, Alberto ^a   Munger, Kassandra L ^a   Lennette, Evelyne T ^c   Spiegelman, Donna ^a   Hernán, Miguel A ^a   Olek, Michael J ^b   Hankinson, Susan E ^a,b   Hunter, David J ^a,b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c Virolab Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPSID PROTEIN; EPSTEIN BARR VIRUS ANTIGEN; VIRUS ANTIBODY;

ADULT; ANTIBODY TITER; ARTICLE; CYTOMEGALOVIRUS; EPSTEIN BARR VIRUS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; VIRUS PATHOGENESIS;

EID: 0035956494     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.286.24.3083     Document Type: Article

References (45)

1. The epidemiology of multiple sclerosis
2. The distinction blurs between an autoimmune versus microbial hypothesis in multiple sclerosis
3. T cells of multiple sclerosis patients target a common environmental peptide that causes encephalitis in mice
4. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection
5. + T cells during the primary immune response to Epstein-Barr virus in vivo
6. + T cells specific for EBV in healthy virus carriers
7. Epstein-Barr virus infection
8. The Epstein-Barr virus in autoimmunity
9. Multiple sclerosis and Epstein-Barr virus
10. A case-control study of multiple sclerosis
11. Epidemiological investigation of the association between infectious mononucleosis and multiple sclerosis
12. Symptomatic Epstein-Barr virus infection and multiple sclerosis
13. Multiple sclerosis and antecedent infections: A case-control study
14. Increased risk of multiple sclerosis after late Epstein-Barr virus infection
15. Multiple sclerosis and age at infection with common viruses
16. Epstein-Barr virus and multiple sclerosis
17. Association between clinical disease activity and EpsteinBarr virus reactivation in MS
18. Epstein-Barr nuclear antigen and viral capsid antigen antibody titers in multiple sclerosis
19. Viral antibody titers: Comparison in patients with multiple sclerosis and rheumatoid arthritis
20. Ubiquitous pathogens: Links between infection and autoimmunity in MS?
21. Hepatitis B vaccination and the risk of multiple sclerosis
22. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
23. Geographic variation of MS incidence in two prospective studies of US women
24. Antibody responses to Epstein-Barr virus-determined nuclearantigen (EBNA)-1 and EBNA-2 in acute and chronic Epstein-Barr virus infection
25. Disease-related differences in antibody patterns against EBVencoded nuclear antigens EBNA 1, EBNA 2 and EBNA 6
26. Cigarette smoking and incidence of multiple sclerosis
27. Applications of stratified analyses methods
28. The significance of Epstein-Barr virus seropositivity in multiple sclerosis patients
29. Epstein-Barr virus uses HLA class II as a cofactor for infection of B lymphocytes
30. Analysis of Epstein-Barr virus (EBV) receptor CD21 on peripheral B lymphocytes of long-term EBV-adults
31. Viral infection in patients with multiple sclerosis and HLA-DR matched controls
32. Epidemiological evidence for causal relationship between EpsteinBarr virus and Burkitt's lymphoma from Ugandan prospective study
33. Epstein-Barr virus
34. Hodgkin's disease and Epstein-Barr virus: Altered antibody pattern before diagnosis
35. Absence of Epstein-Barr virus RNA in multiple sclerosis as assessed by in situ hybridisation
36. Is Epstein-Barr virus present in the CNS of patients with MS?
37. An Epstein Barr virusrelated cross reactive autoimmune response in multiple sclerosis in Norway
38. EBVinduced expression and HLA-DR-restricted presentation by human B cells of alpha B-crystallin, a candidate autoantigen in multiple sclerosis
39. Increased lymphoproliferative response to human herpesvirus type 6A variant in multiple sclerosis patients
40. Human herpesvirus 6 and multiple sclerosis: Systemic active infections in patients with early disease
41. Tissue distribution and variant characterization of human herpesvirus (HHV)-6: Increased prevalence of HHV-6A in patients with multiple sclerosis
42. Cyclic AMP-responsive element-dependent activation of Epstein-Barr virus zebra promoter by human herpesvirus 6
43. Human herpesvirus 6 variant A, but not variant B, infects EBV-positive B lymphoid cells, activating the latent EBV genome through a BZLF-1-dependent mechanism